Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease | Zendy

Andrew M. Moon | Zendy; Stephanie Watkins | Zendy; Anna S. Lok | Zendy; Roberto Firpi-Morell | Zendy; Huy N. Trinh | Zendy; Justin Kupec | Zendy; Cheryl Schoen | Zendy; Brent A. NeuschwanderTetri | Zendy; A. Sidney Barritt | Zendy

Open Access

Opioid Use Is More Common in Nonalcoholic Fatty Liver Disease Patients with Cirrhosis, Higher BMI, and Psychiatric Disease

Author(s) -

Andrew M. Moon,

Stephanie Watkins,

Anna S. Lok,

Roberto Firpi-Morell,

Huy N. Trinh,

Justin Kupec,

Cheryl Schoen,

Brent A. NeuschwanderTetri,

A. Sidney Barritt

Publication year - 2020

Publication title -

digestive diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.879

H-Index - 66

eISSN - 1421-9875

pISSN - 0257-2753

DOI - 10.1159/000511074

Subject(s) - medicine , nonalcoholic fatty liver disease , opioid , odds ratio , cohort , depression (economics) , cirrhosis , opioid use disorder , fatty liver , gastroenterology , disease , receptor , economics , macroeconomics

Opioid use is a topic of growing concern among patients with nonalcoholic fatty liver disease (NAFLD). Given safety concerns of opioids, proactively identifying subgroups of patients with an increased probability of opioid use may encourage practitioners to recommend alternative therapies for pain, thus reducing the likelihood of opioid misuse. This work assessed the prevalence and patient characteristics associated with opioid use in a real-world cohort of patients with NAFLD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research